Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).
Martin Gore(Imperial College London), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Allan Hackshaw(Cancer Research UK), Timothy Perren(University of Leeds), Sean Kehoe(University College Birmingham), Helen Christensen(Cancer Research UK), Raji Ganesan(Birmingham Women’s and Children’s NHS Foundation Trust), Gordon Rustin(Mount Vernon Cancer Centre), Nicholas S. Reed(Beatson West of Scotland Cancer Centre), Richard J. Zaino(Pennsylvania State University), Melanie Mackean(Edinburgh Cancer Research), Jonathan A. Ledermann(London Cancer), G. Dark(Freeman Hospital), Richard T. Penson(Massachusetts General Hospital), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Jeffrey Summers(Maidstone and Tunbridge Wells NHS Trust), Nafisa Wilkinson(University College London Hospitals NHS Foundation Trust), W. Glenn McCluggage(Belfast Health and Social Care Trust), William E. Brady(Pfizer (United States)), Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust)
Cited by 35
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k